Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes
Abstract
Abstract Inflammation is increasingly recognized as a critical factor in acute myeloid leukemia (AML) pathogenesis. We performed blood-based proteomic profiling of 251 inflammatory proteins in 543 patients with newly diagnosed AML. Using a machine learning model, we derived an 8-protein prognostic score termed the leukemia inflammatory risk score (LIRS). Individual proteins were evaluated in multivariable Cox models, and model performance was assessed by cumulative concordance index. Findings were validated in internal and external cohorts across 2 institutions. Blood-based LIRS significantly outperformed the European LeukemiaNet 2022 risk model and was independently prognostic of overall survival after accounting for known clinical and molecular prognostic factors. Oncostatin M receptor was uniquely identified as the strongest independent predictor of survival, early mortality, and induction chemotherapy response, and further validated in an independent assay. These blood-based biomarkers could have significant clinical implications for risk stratification and prognostication in patients with newly diagnosed AML.
Article Details
Authors (22)
Patrick K. Reville
1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Bofei Wang
Department of Chemistry and Chemical Biology
Jennifer Marvin-Peek
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Bin Yuan
Yu-An Kuo
1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Araceli Garza
1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Jessica Root
1Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Wei Qiao
Applied Oral Sciences & Community Dental Care, Faculty of Dentistry
Andrea Arruda
Princess Margaret Cancer Centre, University Health Network
Ivo Veletic
1University of Texas MD Anderson, Pediatrics, Houston, United States
Yiwei Liu
Department of Chemistry
Nicholas J. Short
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Courtney D. DiNardo
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Tapan M. Kadia
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Naval G. Daver
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Philip L. Lorenzi
Koji Sasaki
1The University of Texas MD Anderson Cancer Center, Houston, TX
Steven Kornblau
1University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States
Mark D. Minden
Princess Margaret Cancer Centre, University Health Network
Farhad Ravandi
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Hagop M. Kantarjian
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Hussein A. Abbas
M D Anderson Cancer Center, Houston, Texas, United States